Axel Grothey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6865314/publications.pdf

Version: 2024-02-01

255	27,661	15466 65	5965 160
papers	citations	h-index	g-index

273	273	273	29914
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	6.3	2,276
2	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
3	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology, 2010, 28, 3219-3226.	0.8	1,352
4	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology, 2009, 27, 3677-3683.	0.8	1,166
5	Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. Journal of Clinical Oncology, 2006, 24, 2903-2909.	0.8	1,055
6	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. Journal of Clinical Oncology, 2004, 22, 1209-1214.	0.8	1,007
7	Encorafenib, Binimetinib, and Cetuximab in BRAF V600Eâ€“Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	13.9	918
8	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncology, The, 2015, 16, 499-508.	5.1	753
9	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 370-398.	2.3	707
10	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 2018, 378, 1177-1188.	13.9	699
11	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 874-901.	2.3	698
12	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 359-369.	2.3	675
13	Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). Journal of Clinical Oncology, 2008, 26, 5326-5334.	0.8	654
14	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2005, 23, 8664-8670.	0.8	607
15	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2009, 27, 872-877.	0.8	539
16	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
17	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist, 2020, 25, e936-e945.	1.9	520
18	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	5.1	442

#	Article	IF	Citations
19	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1383.	3.8	412
20	Cyclooxygenase-2: a novel target for cancer chemotherapy?. Journal of Cancer Research and Clinical Oncology, 2001, 127, 411-417.	1.2	381
21	Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement. Annals of Surgical Oncology, 2006, 13, 1261-1268.	0.7	336
22	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews Clinical Oncology, 2009, 6, 507-518.	12.5	332
23	Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. Oncologist, 2009, 14, 862-870.	1.9	292
24	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	5.1	286
25	Biomarkers and surrogate end pointsâ€"the challenge of statistical validation. Nature Reviews Clinical Oncology, 2010, 7, 309-317.	12.5	283
26	^{Non-V600}BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 2624-2630.	0.8	267
27	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. Journal of Clinical Oncology, 2007, 25, 4217-4223.	0.8	258
28	5-fluorouracil and cardiotoxicity: a review. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878014.	1.4	255
29	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	5.1	234
30	A Home-Based Exercise Program to Improve Function, Fatigue, and Sleep Quality in Patients With Stage IV Lung and Colorectal Cancer: A Randomized Controlled Trial. Journal of Pain and Symptom Management, 2013, 45, 811-821.	0.6	223
31	Drug rechallenge and treatment beyond progressionâ€"implications for drug resistance. Nature Reviews Clinical Oncology, 2013, 10, 571-587.	12.5	219
32	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. Oncologist, 2007, 12, 38-50.	1.9	218
33	Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). Journal of Clinical Oncology, 2015, 33, 3416-3422.	0.8	216
34	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology, 2010, 28, 3227-3233.	0.8	198
35	Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 2014, 32, 997-1005.	0.8	191
36	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600Eâ€"Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 2019, 37, 1460-1469.	0.8	188

#	Article	IF	Citations
37	Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 719-728.	2.3	181
38	Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. Journal of Clinical Oncology, 2008, 26, 183-189.	0.8	169
39	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	1.5	169
40	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncology, The, 2019, 20, 1070-1082.	5.1	169
41	Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab. Journal of Clinical Oncology, 2005, 23, 4853-4855.	0.8	164
42	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 1948-1955.	0.8	160
43	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Lancet Oncology, The, 2020, 21, 1620-1629.	5.1	152
44	Randomized Phase III Trial Results of Panitumumab, a Fully Human Antiâ€"Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 29-31.	1.0	141
45	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	3.0	140
46	Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas. Clinical Cancer Research, 2012, 18, 546-554.	3.2	129
47	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	1.5	124
48	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs, 2017, 77, 1091-1103.	4.9	116
49	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene, 2000, 19, 4864-4875.	2.6	106
50	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 852-871.	2.3	104
51	Cisplatin resistance and oncogenes - a review. Anti-Cancer Drugs, 2000, 11, 225-236.	0.7	102
52	Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> geneâ€specific alterations and tumor mutational burden in 1057 microsatellite instabilityâ€high solid tumors. International Journal of Cancer, 2020, 147, 2948-2956.	2.3	102
53	A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 2159-2170.	0.9	96
54	Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials. Journal of Clinical Oncology, 2010, 28, 1936-1941.	0.8	96

#	Article	IF	Citations
55	Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Research, 2003, 63, 513-21.	0.4	95
56	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6Âmonths) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports, 2013, 9, 261-269.	1.0	94
57	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investigational New Drugs, 2015, 33, 740-750.	1.2	94
58	Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOXâ€“Bevacizumab or FOLFIRIâ€“Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study. Oncologist, 2012, 17, 1486-1495.	1.9	91
59	Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncology, The, 2016, 17, 663-670.	5.1	90
60	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24, 185-192.	1.9	89
61	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	0.8	87
62	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology, 2021, 39, 642-651.	0.8	84
63	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
64	Randomized Phase II Trials: Inevitable or Inadvisable?. Journal of Clinical Oncology, 2010, 28, 2641-2647.	0.8	78
65	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. The Lancet Gastroenterology and Hepatology, 2021, 6, 933-946.	3.7	73
66	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. Journal of Clinical Oncology, 2010, 28, 460-465.	0.8	67
67	A FACTOR FOUND IN THE IGG FRACTION OF SERUM OF PATIENTS WITH PARANEOPLASTIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION CAUSES PROLIFERATION OF CULTURED HUMAN MELANOCYTES. Retina, 2012, 32, 1959-1966.	1.0	67
68	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Supportive Care in Cancer, 2016, 24, 5059-5068.	1.0	67
69	Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies. Cancer Journal (Sudbury, Mass), 2008, 14, 170-177.	1.0	65
70	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 3656-3663.	0.8	65
71	Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open, 2020, 5, e000682.	2.0	64
72	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2021, 325, 1277.	3.8	63

#	Article	IF	Citations
73	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	62
74	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. Journal of the National Cancer Institute, 2015, 107, djv216.	3.0	62
75	Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care. Oncologist, 2014, 19, 669-680.	1.9	61
76	Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews, 2020, 86, 101993.	3.4	61
77	New chemotherapy approaches in colorectal cancer. Current Opinion in Oncology, 2001, 13, 275-286.	1.1	57
78	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer, 2016, 16, 467.	1.1	57
79	Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. European Journal of Haematology, 2005, 74, 263-266.	1.1	56
80	Adolescent and Young Adult Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1219-1225.	2.3	49
81	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2015, 41, 653-659.	3.4	49
82	MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Supportive Care in Cancer, 2016, 24, 1071-1078.	1.0	48
83	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. Journal of Clinical Oncology, 2020, 38, 4000-4000.	0.8	48
84	Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer. Molecular Therapy, 2008, 16, 979-984.	3.7	46
85	Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7492-7501.	3.2	45
86	Clinical Trial Designs for Prospective Validation of Biomarkers. Molecular Diagnosis and Therapy, 2005, 5, 317-325.	3.3	44
87	Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiology and Drug Safety, 2014, 23, 726-734.	0.9	43
88	Curable Metastatic Colorectal Cancer. Current Oncology Reports, 2011, 13, 168-176.	1.8	42
89	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. Clinical Colorectal Cancer, 2014, 13, 100-109.	1.0	41
90	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. Journal of Clinical Oncology, 2014, 32, 841-850.	0.8	40

#	Article	IF	Citations
91	Progress in defining first-line and maintenance therapies. Nature Reviews Clinical Oncology, 2015, 12, 73-74.	12.5	39
92	Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist, 2018, 23, 1083-1091.	1.9	39
93	Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. Drugs, 2018, 78, 737-745.	4.9	39
94	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 124-128.	1.0	37
95	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en CancÃ©rologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	0.8	37
96	Treatment options for advanced pancreatic cancer: a review. Expert Review of Anticancer Therapy, 2012, 12, 1327-1336.	1.1	36
97	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist, 2016, 21, 1306-1314.	1.9	36
98	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Therapeutic Advances in Medical Oncology, 2017, 9, 106-126.	1.4	36
99	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology, 2020, 38, 4001-4001.	0.8	35
100	Exploring racial differences in outcome and treatment for metastatic colorectal cancer. Cancer, 2012, 118, 1083-1090.	2.0	34
101	Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist, 2018, 23, 128-134.	1.9	34
102	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist, 2016, 21, 1509-1521.	1.9	33
103	Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. Frontiers in Oncology, 2019, 9, 76.	1.3	33
104	Impact of Circulating Tumor DNAâ€“Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181.	1.5	33
105	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. Journal of Clinical Oncology, 2016, 34, 1182-1189.	0.8	32
106	Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. Clinical Colorectal Cancer, 2019, 18, 52-57.	1.0	32
107	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics: Targets and Therapy, 2008, 2, 223.	3.0	31
108	Chemotherapy Maintenance. Cancer Journal (Sudbury, Mass), 2016, 22, 199-204.	1.0	31

#	Article	IF	Citations
109	Landscape of KRAS^{G12C}, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precision Oncology, 2022, 6, e2100245.	1.5	31
110	Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and Complications. Oncologist, 2012, 17, 725-731.	1.9	30
111	MODULâ€"a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1197-1204.	1.2	30
112	N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer. Clinical Colorectal Cancer, 2005, 5, 211-213.	1.0	29
113	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). Cancer, 2007, 110, 670-677.	2.0	29
114	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29
115	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 60-64.	1.0	28
116	Antiangiogenesis agents in colorectal cancer. Current Opinion in Oncology, 2010, 22, 374-380.	1.1	28
117	Clinical Validation of a Machine-learningâ€"derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	3.2	28
118	Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.. Journal of Clinical Oncology, 2020, 38, 4004-4004.	0.8	28
119	Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. Clinical Colorectal Cancer, 2004, 4, 46-50.	1.0	27
120	A new prognostic and predictive tool for shared decision making in stage III colon cancer. European Journal of Cancer, 2020, 138, 182-188.	1.3	27
121	Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial. Clinical Colorectal Cancer, 2006, 6, 261-264.	1.0	26
122	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 301-319.	1.4	26
123	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open, 2020, 5, e000942.	2.0	26
124	Prognostic webâ€based models for stage II and III colon cancer. Cancer, 2011, 117, 4155-4165.	2.0	25
125	Rationale for metronomic chemotherapy in phase III trials. Nature Reviews Clinical Oncology, 2015, 12, 313-314.	12.5	25
126	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist, 2020, 25, 404-413.	1.9	25

#	Article	IF	Citations
127	Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer. Oncology, 2010, 79, 389-399.	0.9	24
128	Pembrolizumab in MSI-Hâ€“dMMR Advanced Colorectal Cancer â€” A New Standard of Care. New England Journal of Medicine, 2020, 383, 2283-2285.	13.9	24
129	FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer. Journal of Clinical Oncology, 2005, 23, 3311-3313.	0.8	23
130	Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators. Seminars in Oncology, 2010, 37, 39-46.	0.8	21
131	Is obesity an advantage in patients with colorectal cancer?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1339-1342.	1.4	21
132	Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. Journal of the American Society of Echocardiography, 2019, 32, 267-276.	1.2	21
133	Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 961-969.	1.1	20
134	Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Supportive Care in Cancer, 2005, 13, 26-31.	1.0	19
135	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1451-1455.	2.9	19
136	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open, 2021, 11, e047831.	0.8	19
137	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. Journal of the National Cancer Institute, 2015, 107, djv239.	3.0	18
138	First- and second-line therapy of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2006, 6, 921-930.	1.1	17
139	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 316-325.	3.2	17
140	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	0.5	17
141	Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741. Oncologist, 2011, 16, 859-867.	1.9	16
142	KRAS and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice. Oncologist, 2011, 16, 1061-1068.	1.9	16
143	The search for treatments to reduce chemotherapy-induced peripheral neuropathy. Journal of Clinical Investigation, 2014, 124, 72-74.	3.9	16
144	A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. Oncologist, 2018, 23, 679-685.	1.9	16

#	Article	IF	Citations
145	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Management and Research, 2017, Volume 9, 149-158.	0.9	15
146	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open, 2018, 3, e000347.	2.0	15
147	Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 611-615.	2.3	15
148	Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Clinical Advances in Hematology and Oncology, 2015, 13, 514-7.	0.3	15
149	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open, 2021, 6, 100328.	2.0	15
150	Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. Clinical and Experimental Metastasis, 1999, 17, 171-176.	1.7	14
151	Oxaliplatin plus Oral Fluoropyrimidines in Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S37-S42.	1.0	14
152	New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer: Summary Statement from 2007 Santa Monica Conference. Clinical Cancer Research, 2007, 13, 6853s-6856s.	3.2	14
153	Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 4587-4598.	3.2	14
154	Future Directions in Vascular Endothelial Growth Factorâ€“Targeted Therapy for Metastatic Colorectal Cancer. Seminars in Oncology, 2006, 33, S41-S49.	0.8	13
155	When less is more: maintenance therapy in colorectal cancer. Lancet, The, 2015, 385, 1808-1810.	6.3	13
156	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	1.3	13
157	Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.. Journal of Clinical Oncology, 2021, 39, 3513-3513.	0.8	13
158	A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. Journal of Cancer Research and Clinical Oncology, 2001, 127, 96-100.	1.2	12
159	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091091.	1.4	12
160	Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. JCO Oncology Practice, 2021, 17, 383-402.	1.4	12
161	Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anti-Cancer Drugs, 1998, 9, 405-409.	0.7	11
162	Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1097-1101.	2.3	11

#	Article	IF	Citations
163	Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. Expert Review of Gastroenterology and Hepatology, 2015, 9, 273-276.	1.4	11
164	Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. Clinical Colorectal Cancer, 2018, 17, e183-e187.	1.0	11
165	Regorafenib in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 137-145.	0.9	10
166	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). Journal of Geriatric Oncology, 2018, 9, 24-31.	0.5	10
167	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers, 2020, 12, 1319.	1.7	10
168	Regorafenib for metastatic colorectal cancer â€“ Authors' reply. Lancet, The, 2013, 381, 1538-1539.	6.3	9
169	VEGF inhibition beyond tumour progression. Lancet Oncology, The, 2013, 14, 2-3.	5.1	9
170	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. Supportive Care in Cancer, 2019, 27, 3869-3875.	1.0	9
171	Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancerâ€”Fact or Fiction?. JAMA Oncology, 2020, 6, 823.	3.4	9
172	Comparing and Validating Simple Measures of Patient- Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiology & Pain Management, 2015, 2, .	0.1	9
173	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	2.3	9
174	Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Statistical Methods in Medical Research, 2008, 17, 529-535.	0.7	8
175	Adjuvant Therapy for Colon Cancer. JAMA Oncology, 2016, 2, 1133.	3.4	8
176	Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 1417-1427.	0.7	8
177	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110244.	1.4	8
178	Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting. Oncology Research and Treatment, 2005, 28, 88-92.	0.8	7
179	Do All Patients with Metastatic Colorectal Cancer Need Chemotherapy Until Disease Progression?. Clinical Colorectal Cancer, 2006, 6, 196-201.	1.0	7
180	Review: Medical treatment of advanced colorectal cancer in 2009. Therapeutic Advances in Medical Oncology, 2009, 1, 55-68.	1.4	7

#	Article	IF	Citations
181	The Role of Chemotherapy in Managing Patients With Resectable Liver Metastases. Cancer Journal (Sudbury, Mass), 2010, 16, 125-131.	1.0	7
182	Does Stage II Colorectal Cancer Need to Be Redefined?. Clinical Cancer Research, 2011, 17, 3053-3055.	3.2	7
183	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949.	1.0	7
184	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC). American Journal of Hematology, 2017, 92, 1004-1010.	2.0	7
185	Evolution of Cancer Care in Response to the COVID â€19 Pandemic. Oncologist, 2020, 25, e1426-e1427.	1.9	7
186	EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?. Lancet Oncology, The, 2020, 21, 324-326.	5.1	7
187	Regorafenib in metastatic colorectal cancer. Clinical Advances in Hematology and Oncology, 2012, 10, 324-5.	0.3	7
188	Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?. Clinical Cancer Research, 2007, 13, 6909s-6912s.	3.2	6
189	North Central Cancer Treatment Groupâ€"Achievements and Perspectives. Seminars in Oncology, 2008, 35, 530-544.	0.8	6
190	A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer. Nature Clinical Practice Oncology, 2009, 6, 10-11.	4.3	6
191	Should Oncologists Routinely Discuss Fertility Preservation With Cancer Patients of Childbearing Age?. Mayo Clinic Proceedings, 2011, 86, 6-7.	1.4	6
192	The role of regorafenib in metastatic colorectal cancer. Lancet Oncology, The, 2015, 16, 596-597.	5.1	6
193	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. Cancer Management and Research, 2021, Volume 13, 5523-5533.	0.9	6
194	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy Â± biologic: Findings from 9,092 pts in the ARCAD database.. Journal of Clinical Oncology, 2017, 35, 3535-3535.	0.8	6
195	Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.. Journal of Clinical Oncology, 2018, 36, 3599-3599.	0.8	6
196	Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. Annals of Surgical Oncology, 2010, 17, 947-949.	0.7	5
197	Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Reports in Oncological Medicine, 2015, 2015, 1-7.	0.2	5
198	Evidence in Favor of Standard Surgical Treatment for Rectal Cancer. JAMA Oncology, 2017, 3, 885.	3.4	5

#	Article	IF	Citations
199	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemporary Clinical Trials Communications, 2020, 17, 100492.	0.5	5
200	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist, 2021, 26, 610-618.	1.9	5
201	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist, 2021, 26, 651-659.	1.9	5
202	Developments in combination chemotherapy for colorectal cancer. Expert Review of Anticancer Therapy, 2004, 4, 627-637.	1.1	4
203	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. Hpb, 2013, 15, 116-118.	0.1	4
204	Phase III Randomized, Placebo(Pl)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1. Annals of Oncology, 2013, 24, iv24.	0.6	4
205	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes and Control, 2019, 30, 757-765.	0.8	4
206	Microsatellite Stable Colorectal Liver Metastasesâ€"Understanding the Mechanisms of Immune Resistance. JAMA Network Open, 2021, 4, e2119025.	2.8	4
207	Metastatic extramammary Paget's disease responding to weekly paclitaxel. BMJ Case Reports, 2015, 2015, bcr2014208653-bcr2014208653.	0.2	4
208	Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. Anti-Cancer Drugs, 1999, 10, 545-550.	0.7	3
209	Reply to D.J. Stewart. Journal of Clinical Oncology, 2010, 28, e652-e653.	0.8	3
210	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110205.	1.4	3
211	Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, 3583-3583.	0.8	3
212	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. Current Colorectal Cancer Reports, 2021, 17, 55-68.	1.0	3
213	Personalizing Treatment for Rectal Cancer. JAMA Network Open, 2020, 3, e2030508.	2.8	3
214	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	1.4	3
215	Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials. Journal of Clinical Oncology, 2007, 25, 3191-3193.	0.8	2
216	Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 682-685.	2.3	2

#	Article	IF	Citations
217	New Adjuvant Trial Designs in Colon Cancer. Current Colorectal Cancer Reports, 2015, 11, 326-334.	1.0	2
218	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Investigational New Drugs, 2016, 34, 96-103.	1.2	2
219	Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. Lancet Oncology, The, 2017, 18, 1427-1428.	5.1	2
220	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. Journal of Clinical Oncology, 2018, 36, 612-612.	0.8	2
221	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
222	Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?. Nature Clinical Practice Oncology, 2006, 3, 22-23.	4.3	1
223	Reply to S.A. Kesikli et al. Journal of Clinical Oncology, 2012, 30, 2288-2289.	0.8	1
224	O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC). Annals of Oncology, 2012, 23, iv15-iv16.	0.6	1
225	The Challenge to Optimize Medical Therapy for Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, djt442-djt442.	3.0	1
226	Distinctive Tumor Biology of MSI-High Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 281-287.	1.0	1
227	Colorectal cancer: how to teach an old drug new tricks. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 384-385.	8.2	1
228	Adverse event development in clinical oncology trials â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e264-e265.	5.1	1
229	Impact of Molecular Tumor Board (MTB) on precision oncology in a community setting. Gynecologic Oncology, 2021, 162, S180.	0.6	1
230	Does Lifestyle Cause Colorectal Cancer?. , 0, , 1-13.		1
231	The Role of the Colorectal Nurse Specialist in the Management of Colorectal Cancer. , 0, , 153-166.		1
232	Risk assessment in stage II colon cancer: to treat or not to treat?. Oncology, 2010, 24, 1-2.	0.4	1
233	Should bevacizumab be continued beyond progression in colorectal cancer?. Current Colorectal Cancer Reports, 2008, 4, 139-143.	1.0	0
234	Reply to F. Montagnani et al. Journal of Clinical Oncology, 2009, 27, e134-e135.	0.8	0

#	Article	IF	Citations
235	Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial. Current Colorectal Cancer Reports, 2009, 5, 65-66.	1.0	0
236	Strategies for Managing Chemotherapy-Induced Sensory Neuropathy. Current Colorectal Cancer Reports, 2010, 6, 126-132.	1.0	0
237	Recent developments in therapy for gastrointestinal cancers. Community Oncology, 2011, 8, 4-8.	0.2	0
238	Adjuvant Hepatic Arterial Infusional Chemotherapy. Annals of Surgery, 2011, 254, 857-859.	2.1	0
239	Reduced Chemotherapy Duration: A Good Idea?. Current Colorectal Cancer Reports, 2011, 7, 241-245.	1.0	0
240	Reply to A. Chan et al. Journal of Clinical Oncology, 2011, 29, e490-e491.	0.8	0
241	Reply to S.B. Park et al. Journal of Clinical Oncology, 2011, 29, e555-e556.	0.8	0
242	Reply to M. MandalÃ et al. Journal of Clinical Oncology, 2012, 30, 1895-1895.	0.8	0
243	Establishing a Standard of Care for Small Bowel Adenocarcinomas: Challenges and Lessons Learned. Oncologist, 2012, 17, 1133-1134.	1.9	0
244	S-1 in colorectal cancer: a new standard of care?. Lancet Oncology, The, 2012, 13, 1068-1070.	5.1	0
245	Optimal Treatment Strategies for Localized and Advanced Microsatellite Instabilityâ€“High Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 36-41.	1.0	0
246	European Society for Medical Oncology Copenhagen update: potential practice-changing findings. Therapeutic Advances in Medical Oncology, 2017, 9, 4-12.	1.4	0
247	Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.. Journal of Clinical Oncology, 2021, 39, 3517-3517.	0.8	0
248	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.. Journal of Clinical Oncology, 2012, 30, 446-446.	0.8	0
249	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research, 2018, 7, 137-146.	0.5	0
250	Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity. Gastrointestinal Cancer Research: GCR, 2008, 2, 258-60.	0.8	0
251	Waiting in line for cancer treatments?. Gastrointestinal Cancer Research: GCR, 2011, 4, 147-9.	0.8	0
252	What can the Pathologist Tell the Multidisciplinary Team about Rectal Cancer Resection?. , 0, , 31-45.		0

#	Article	IF	Citations
253	MRI-Directed Rectal Cancer Surgery. , 0, , 46-59.		0
254	Minimally Invasive Surgeryâ€“ Where are We? Laparoscopic Surgery for Cancer of the Colon and Rectum. , 0, , 60-72.		0
255	Introduction to special issue on biomarker-based clinical trial designs in oncology. Chinese Clinical Oncology, 2015, 4, 28.	0.4	0